Class I HDAC inhibitor mocetinostat induces apoptosis by activation of miR-31 expression and suppression of E2F6

Cell Death Discovery

Volumn 2, Issue 1, 2016, Pages

  Zhang, Q ^a   Sun, M ^a   Zhou, S ^a   Guo, B ^a  

^a NORTH DAKOTA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85071831761     PISSN: None     EISSN: 20587716     Source Type: Journal    
DOI: 10.1038/cddiscovery.2016.36     Document Type: Article

References (38)

1. Gray SG, Ekstrom TJ. The human histone deacetylase family. Exp Cell Res 2001; 262: 75–83.
2. Strahl BD, Allis CD. The language of covalent histone modifications. Nature 2000; 403: 41–45.
3. Minucci S, Pelicci PG. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 2006; 6: 38–51.
4. Choudhary C, Kumar C, Gnad F, Nielsen ML, Rehman M, Walther TC et al. Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 2009; 325: 834–840.
5. Haberland M, Montgomery RL, Olson EN. The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nat Rev Genet 2009; 10: 32–42.
6. Weichert W, Roske A, Gekeler V, Beckers T, Ebert MP, Pross M et al. Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysis. Lancet Oncol 2008; 9: 139–148.
7. Weichert W, Roske A, Gekeler V, Beckers T, Stephan C, Jung K et al. Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy. Br J Cancer 2008; 98: 604–610.
8. Weichert W, Roske A, Niesporek S, Noske A, Buckendahl AC, Dietel M et al. Class I histone deacetylase expression has independent prognostic impact in human colorectal cancer: specific role of class I histone deacetylases in vitro and in vivo. Clin Cancer Res 2008; 14: 1669–1677.
9. Slingerland M, Guchelaar HJ, Gelderblom H. Histone deacetylase inhibitors: an overview of the clinical studies in solid tumors. Anti-cancer Drugs 2014; 25: 140–149.
10. Fournel M, Bonfils C, Hou Y, Yan PT, Trachy-Bourget MC, Kalita A et al. MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo. Mol Cancer Ther 2008; 7: 759–768.
11. Bonfils C, Kalita A, Dubay M, Siu LL, Carducci MA, Reid G et al. Evaluation of the pharmacodynamic effects of MGCD0103 from preclinical models to human using a novel HDAC enzyme assay. Clin Cancer Res 2008; 14: 3441–3449.
12. Sikandar S, Dizon D, Shen X, Li Z, Besterman J, Lipkin SM. The class I HDAC inhibitor MGCD0103 induces cell cycle arrest and apoptosis in colon cancer initiating cells by upregulating Dickkopf-1 and non-canonical Wnt signaling. Oncotarget 2010; 1: 596–605.
13. El-Khoury V, Moussay E, Janji B, Palissot V, Aouali N, Brons NH et al. The histone deacetylase inhibitor MGCD0103 induces apoptosis in B-cell chronic lymphocytic leukemia cells through a mitochondria-mediated caspase activation cascade. Mol Cancer Ther 2010; 9: 1349–1360.
14. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell 2009; 136: 215–233.
15. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116: 281–297.
16. Kota J, Chivukula RR, O'Donnell KA, Wentzel EA, Montgomery CL, Hwang HW et al. Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell 2009; 137: 1005–1017.
17. Chen CZ, Li L, Lodish HF, Bartel DP. MicroRNAs modulate hematopoietic lineage differentiation. Science 2004; 303: 83–86.
18. Zhang J, Jima DD, Jacobs C, Fischer R, Gottwein E, Huang G et al. Patterns of microRNA expression characterize stages of human B-cell differentiation. Blood 2009; 113: 4586–4594.
19. Poy MN, Eliasson L, Krutzfeldt J, Kuwajima S, Ma X, Macdonald PE et al. A pancreatic islet-specific microRNA regulates insulin secretion. Nature 2004; 432: 226–230.
20. Ma L, Teruya-Feldstein J, Weinberg RA. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature 2007; 449: 682–688.
21. Hermeking H. The miR-34 family in cancer and apoptosis. Cell Death Differ 2009; 17: 193–199.
22. Bhatnagar N, Li X, Padi SK, Zhang Q, Tang MS, Guo B. Downregulation of miR-205 and miR-31 confers resistance to chemotherapy-induced apoptosis in prostate cancer cells. Cell Death Dis 2010; 1: e105.
23. Lin PC, Chiu YL, Banerjee S, Park K, Mosquera JM, Giannopoulou E et al. Epigenetic repression of miR-31 disrupts androgen receptor homeostasis and contributes to prostate cancer progression. Cancer Res 2013; 73: 1232–1244.
24. McCabe MT, Brandes JC, Vertino PM. Cancer DNA methylation: molecular mechanisms and clinical implications. Clin Cancer Res 2009; 15: 3927–3937.
25. Marks PA. Discovery and development of SAHA as an anticancer agent. Oncogene 2007; 26: 1351–1356.
26. Yang WW, Wang ZH, Zhu Y, Yang HT. E2F6 negatively regulates ultraviolet-induced apoptosis via modulation of BRCA1. Cell Death Differ 2007; 14: 807–817.
27. Yang WW, Shu B, Zhu Y, Yang HT. E2F6 inhibits cobalt chloride-mimetic hypoxia-induced apoptosis through E2F1. Mol Biol Cell 2008; 19: 3691–3700.
28. Danial NN, Korsmeyer SJ. Cell death: critical control points. Cell 2004; 116: 205–219.
29. Jiang P, Du W, Wu M. p53 and Bad: remote strangers become close friends. Cell research 2007; 17: 283–285.
30. Danial NN. BAD: undertaker by night, candyman by day. Oncogene 2008; 27: S53–S70.
31. Sharpe B, Beresford M, Bowen R, Mitchard J, Chalmers AD. Searching for prostate cancer stem cells: markers and methods. Stem Cell Rev 2013; 9: 721–730.
32. Ajani JA, Song S, Hochster HS, Steinberg IB. Cancer stem cells: the promise and the potential. Semin Oncol 2015; 42: S3–S17.
33. Luger SM, O'Connell CL, LKlimek V, Cooper MA, Besa EC, Rossetti JM et al. A phase II study of mocetinostat, an oral isotype-selective histone deacetylase (HDAC) inhibitor, in combination with 5-azacitidine in patients with myelodysplastic syndrome (MDS). J Clin Oncol 2013; 31(suppl): abstr 7116.
34. Younes A, Oki Y, Bociek RG, Kuruvilla J, Fanale M, Neelapu S et al. Mocetinostat for relapsed classical Hodgkin's lymphoma: an open-label, single-arm, phase 2 trial. Lancet Oncol 2011; 12: 1222–1228.
35. Blum KA, Advani A, Fernandez L, Van Der Jagt R, Brandwein J, Kambhampati S et al. Phase II study of the histone deacetylase inhibitor MGCD0103 in patients with previously treated chronic lymphocytic leukaemia. Br J Haematol 2009; 147: 507–514.
36. Willis SN, Adams JM. Life in the balance: how BH3-only proteins induce apoptosis. Curr Opin Cell Biol 2005; 17: 617–625.
37. Germann M, Wetterwald A, Guzman-Ramirez N, van der Pluijm G, Culig Z, Cecchini MG et al. Stem-like cells with luminal progenitor phenotype survive castration in human prostate cancer. Stem Cells 2012; 30: 1076–1086.
38. O'Dwyer K, Maslak P. Azacitidine and the beginnings of therapeutic epigenetic modulation. Expert Opin Pharmacother 2008; 9: 1981–1986.